Business Context and Reporting Period
Company: RedHill Biopharma Ltd.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: RedHill is a specialty biopharmaceutical company focused on gastrointestinal (GI), infectious diseases, and oncology. Its primary commercial product is Talicia (for H. pylori infection). The company maintains a pipeline of five therapeutic candidates, including opaganib and RHB-107. Following the 2023 divestiture of Movantik, the company lost its primary revenue source and is currently focused on commercializing Talicia and advancing its pipeline while seeking strategic transactions.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 (USD) | 2023 (USD) |
|---|---|---|
| Net Revenues | $8.0 million | $6.5 million |
| Net Income (Loss) | $(8.3) million | $23.9 million |
| Operating Loss | $(14.6) million | $12.6 million (Income) |
| Gross Profit | $4.9 million | $3.1 million |
| Cash and Cash Equivalents | $4.6 million | $5.6 million |
| Total Cash (incl. Restricted) | $4.8 million | $6.5 million |
| Net Cash Used in Operating Activities | $(9.4) million | $(35.8) million |
| Accumulated Deficit | $(414.8) million | $(407.7) million |
| Total Liabilities | $22.7 million | $21.0 million |
Note: 2023 Net Income was significantly driven by a one-time gain of $44.1 million from the divestiture of Movantik and debt extinguishment. 2024 results reflect a return to operational losses.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 23% to $8.0 million, driven by $1.0 million in revenue from the UAE partnership for Talicia and a reduction in contra-revenues (product returns) related to the former Movantik business.
- Expense Reduction: Selling, Marketing, and General & Administrative (G&A) expenses decreased significantly from $31.0 million in 2023 to $15.5 million in 2024 due to workforce downsizing and cost-reduction measures following the Movantik sale.
- One-Time Items: The 2023 income included a $44.1 million gain from the Movantik transaction. In 2024, the company recognized a $2.3 million loss related to the Global Termination Agreement with HCRM affiliates, settling remaining Movantik liabilities.
- Liquidity: Cash balance decreased by approximately $1.7 million year-over-year. The company terminated its previous At-The-Market (ATM) program with Cantor Fitzgerald and initiated a new ATM facility with H.C. Wainwright in early 2025.
Guidance, Outlook, Risks, and Contingencies
Going Concern Warning
Management has expressed substantial doubt about the company's ability to continue as a going concern. As of December 31, 2024, cash resources ($4.8 million) are insufficient to fund operations for the next 12 months. The company requires significant additional capital to finance losses and negative cash flows.
Strategic Outlook
- Capital Raising: The company is actively pursuing equity or debt financing and strategic business transactions (including potential asset divestitures) to secure liquidity.
- Commercialization: Focus remains on Talicia commercialization in the U.S. and UAE. The company recently entered an exclusive license agreement with Hyloris Pharmaceuticals for RHB-102 (Bekinda) outside North America (Feb 2025).
- Government Funding Risk: Funding for the RHB-107 Phase 2 trial (ACESO PROTECT) was notified for termination in January 2025, requiring the study to cease enrollment early. This may impact the ability to draw conclusions on efficacy.
Key Risks
- Nasdaq Compliance: The company does not currently meet the minimum shareholders' equity requirement ($2.5 million) for Nasdaq listing and must cure this non-compliance.
- Internal Controls: A material weakness in internal control over financial reporting (related to revenue allowance calculations) identified in 2022 remains unremediated as of December 31, 2024.
- Legal Proceedings: The company obtained a summary judgment of approximately $8.0 million against Kukbo Co. Ltd. in December 2024. However, Kukbo has appealed, and collection is uncertain. Legal fees are contingent on recovery.
- Geopolitical: Operations in Israel are subject to risks from ongoing regional conflicts, which could disrupt operations or supply chains.
Investor Verification Checklist
- Liquidity Runway: Verify the status of new financing efforts and the sufficiency of the new ATM facility with H.C. Wainwright to cover the 12-month operating deficit.
- Nasdaq Status: Monitor the company's progress in curing the shareholders' equity deficiency to avoid delisting.
- Internal Control Remediation: Review updates on the remediation plan for the material weakness in financial reporting controls.
- Kukbo Litigation: Track the appeal process and likelihood of collecting the $8.0 million judgment.
- RHB-107 Trial Status: Assess the impact of the terminated government funding on the RHB-107 clinical trial and future development plans.
- Talicia Sales: Monitor U.S. sales performance and reimbursement rates for Talicia as the primary revenue driver.